Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor–Positive Early Breast Cancer: Lights and Shadows

Documenti analoghi

• Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials
  di: Regan, Meredith M., et al.
  Pubblicazione: (2016)
• Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials
  di: Regan, Meredith M., et al.
  Pubblicazione: (2013)
• Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT
  di: Pagani, Olivia, et al.
  Pubblicazione: (2020)
• Predictive value and clinical utility of centrally-assessed ER, PgR and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
  di: Regan, Meredith M., et al.
  Pubblicazione: (2015)
• Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials
  di: Bernhard, Jürg, et al.
  Pubblicazione: (2015)